Table 3. Interventions in COVID-19 subjects with and without retinopathy.
| Interventions | All (n = 60) | COVID-19 Retinopathy (n = 12) | No COVID-19 Retinopathy (n = 48) | Odds Ratio (95% CI) | p-value |
|---|---|---|---|---|---|
| Mechanical Vent | 17 (28%) | 5 (42%) | 12 (25%) | 3.33 (0.55, 20.22) | 0.23 |
| Vasopressors | 4 (7%) | 2 (17%) | 2 (4%) | 4.60 (0.58, 36.67) | 0.17 |
| Continuous renal replacement therapy | 2 (3%) | 1 (8%) | 1 (2%) | 4.27 (0.25, 73.75) | 0.36 |
| Extracorporeal Membrane O2 (ECMO) | 8 (13%) | 4 (33%) | 4 (8%) | 5.50 (1.14, 26.63) | 0.04 |
| Lovenox | 27 (45%) | 3 (25%) | 24 (50%) | 0.33 (0.08, 1.38) | 0.20 |
| Anticoagulation beyond Lovenox | 39 (65%) | 10 (83%) | 29 (48%) | 3.27 (0.65, 16.63) | 0.19 |
| Corticosteroid | 25 (42%) | 6 (50%) | 19 (40%) | 1.52 (0.43, 5.44) | 0.53 |